Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance

 
• By Joseph Haas

Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.

OvarianCancer_1200x675
Clovis's timeline for adding to Rubraca's ovarian cancer labeling is uncertain

More from Clinical Trials

More from R&D